MicroRNA-33a and microRNA-33b are encoded within the mammalian SREBF1 and SRBF2 genes, respectively, and both SREBF1 and ...

In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation ...

For Becker muscular dystrophy, the company reported positive data from MESA, which is an open-label extension trial that provides continued access to sevasemten for participants previously ...

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies Jun. 26, 2025 6:00 AM ET Edgewise Therapeutics, Inc. (EWTX) ...

Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne.

Becker Muscular Dystrophy, much like Duchenne Muscular Dystrophy, is a type of genetic disorder that causes progressive muscle weakness and degeneration over time, primarily in males.

Becker Muscular Dystrophy, like Duchenne Muscular Dystrophy (DMD), is a progressive X-linked neuromuscular disorder that results in significant skeletal and cardiac muscle deterioration over time.

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseasesCapricor remains on track for the ...